Lorena Lorefice

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8162646/publications.pdf

Version: 2024-02-01

66 papers	1,565 citations	331538 21 h-index	345118 36 g-index
67 all docs	67 docs citations	67 times ranked	2755 citing authors

#	Article	IF	Citations
1	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 448-450.	0.9	53
2	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. Neurology and Therapy, 2022, 11, 39-49.	1.4	12
3	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.3	9
4	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. Frontiers in Neurology, 2021, 12, 679355.	1.1	2
5	Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. Frontiers in Immunology, 2021, 12, 728677.	2.2	7
6	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. Disability and Rehabilitation, 2020, 42, 737-742.	0.9	6
7	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
8	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	0.9	14
9	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	2.1	39
10	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	0.9	3
11	Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers. International Journal of Environmental Research and Public Health, 2020, 17, 8848.	1.2	15
12	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	0.9	2
13	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.3	1
14	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. Multiple Sclerosis and Related Disorders, 2020, 46, 102564.	0.9	5
15	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsingâ€“Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
16	The impact of deep grey matter volume on cognition in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102351.	0.9	11
17	Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis. Multiple Sclerosis International, 2019, 2019, 1-6.	0.4	6
18	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Neurotherapeutics, 2019, 16, 797-807.	2.1	17

#	Article	IF	Citations
19	Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. Journal of Neurology, 2019, 266, 1405-1411.	1.8	31
20	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study.. Multiple Sclerosis and Related Disorders, 2019, 27, 74-78.	0.9	20
21	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. Multiple Sclerosis Journal, 2019, 25, 23-30.	1.4	11
22	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	1.4	38
23	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A caseâ€“control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	1.8	14
24	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. Multiple Sclerosis and Related Disorders, 2018, 20, 104-108.	0.9	9
25	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. Multiple Sclerosis and Related Disorders, 2018, 22, 8-11.	0.9	9
26	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	1.8	21
27	Long-term follow-up more than 10Âyears after HSCT: a monocentric experience. Journal of Neurology, 2018, 265, 410-416.	1.8	10
28	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work, 2018, 60, 263-270.	0.6	30
29	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. Journal of Neurology, 2018, 265, 1328-1333.	1.8	15
30	The burden of multiple sclerosis and patientsâ€™ coping strategies. BMJ Supportive and Palliative Care, 2018, 8, 38-40.	0.8	25
31	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. Multiple Sclerosis Journal, 2018, 24, 231-233.	1.4	3
32	Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. Neurological Sciences, 2018, 39, 389-390.	0.9	3
33	PML in a person with multiple sclerosis. Neurology, 2018, 90, 83-85.	1.5	23
34	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. Multiple Sclerosis and Related Disorders, 2018, 23, 83-87.	0.9	9
35	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1093-1099.	1.0	15
36	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurology, 2018, 18, 67.	0.8	27

#	Article	IF	Citations
37	Association between brain atrophy and cognitive motor interference in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 208-211.	0.9	10
38	Top-down proteomic profiling of human saliva in multiple sclerosis patients. Journal of Proteomics, 2018, 187, 212-222.	1.2	40
39	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2017, 15, 1-6.	0.9	26
40	Overexpression of the Cytokine BAFF and Autoimmunity Risk. New England Journal of Medicine, 2017, 376, 1615-1626.	13.9	301
41	Charcotâ€“Marieâ€“Tooth disease: genetic subtypes in the Sardinian population. Neurological Sciences, 2017, 38, 1019-1025.	0.9	11
42	â€˜Timed up and goâ€™ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. Journal of Neurology, 2017, 264, 2201-2204.	1.8	13
43	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. International Journal of Biochemistry and Cell Biology, 2017, 93, 148-155.	1.2	44
44	Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 173-180.	1.4	13
45	TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy. Current Medical Imaging, 2017, 14, 95-98.	0.4	0
46	¹ H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e185.	3.1	68
47	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. Multiple Sclerosis and Related Disorders, 2016, 10, 187-191.	0.9	61
48	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. Multiple Sclerosis and Related Disorders, 2016, 7, 65-67.	0.9	5
49	Facial synkinesis as a first symptom of multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1499-1501.	1.4	1
50	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. PLoS ONE, 2016, 11, e0163313.	1.1	15
51	Oral Agents in Multiple Sclerosis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2015, 14, 15-25.	1.1	4
52	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. Journal of the Neurological Sciences, 2015, 349, 249-250.	0.3	12
53	Progressive multiple sclerosis and mood disorders. Neurological Sciences, 2015, 36, 1625-1631.	0.9	14
54	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. Neurological Sciences, 2015, 36, 2213-2220.	0.9	1

#	Article	IF	Citations
55	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. Journal of the Neurological Sciences, 2015, 357, 229-234.	0.3	6
56	The burden of multiple sclerosis variants in continental Italians and Sardinians. Multiple Sclerosis Journal, 2015, 21, 1385-1395.	1.4	10
57	Influence of treatments in multiple sclerosis disability: A cohort study. Multiple Sclerosis Journal, 2015, 21, 433-441.	1.4	32
58	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurological Sciences, 2014, 35, 401-408.	0.9	19
59	Long-term benefits of induction therapy in NMO: a case report. Neurological Sciences, 2014, 35, 1831-1832.	0.9	2
60	The risk of Bipolar Disorders in Multiple Sclerosis. Journal of Affective Disorders, 2014, 155, 255-260.	2.0	61
61	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. Journal of Affective Disorders, 2014, 167, 192-197.	2.0	40
62	Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis. Inflammation and Allergy: Drug Targets, 2014, 13, 134-143.	1.8	4
63	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. BMC Neurology, 2013, 13, 177.	0.8	48
64	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. PLoS ONE, 2013, 8, e59790.	1.1	25
65	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. PLoS ONE, 2012, 7, e41678.	1.1	38
66	Epidemiology of multiple sclerosis in south-western Sardinia. Multiple Sclerosis Journal, 2011, 17, 1282-1289.	1.4	66